Lung function and quality of life remained stable over three years of follow-up among people with chronic obstructive pulmonary disease (COPD) treated with targeted lung denervation (TLD) — a new therapy developed by Nuvaira — according to the results of a clinical trial. That trial, called AIRFLOW-1 (…
Two Montreal-based foundations are joining forces to boost research and care into complex and chronic respiratory disorders, including chronic obstructive pulmonary disease (COPD). The merging of the McGill University Health Centre (MUHC) Foundation and the Montreal Chest Institute (MCI) Foundation comes as the MUHC opens a $10 million…
A new collaboration is seeking to bring quantitative imaging analysis to diagnosis and care of patients with chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and emphysema. The agreement is between Spesana, a healthcare platform focused on molecular diagnostics and in building an accessible database for physicians,…
The U.S. Food and Drug Administration (FDA) has cleared the start of an international pivotal trial to test the RheOx System, Gala Therapeutics’ medical device, in adults with chronic obstructive pulmonary disease (COPD) who have moderate to severe chronic bronchitis. “Chronic bronchitis is a debilitating disease which results…
Weight loss and a low body mass index (BMI) are associated with worse mortality outcomes among men with chronic obstructive pulmonary disease (COPD) in Japan, according to a new study. The study, “Low BMI and weight loss aggravate COPD mortality in men, findings from a large…
A new algorithm-based approach was developed to identify patients at risk of being misdiagnosed with chronic obstructive pulmonary disease (COPD). Researchers believe this may become an important tool to help healthcare providers in diagnosing several diseases. “Our new algorithm can find the patients who have such an unusual disease…
The Scottish Medicines Consortium (SMC) has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval specifically covers adults with moderate to severe disease who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a…
As part of its Catalyst Grant program, the American Lung Association (ALA) has awarded $50,000 for a project aimed at regenerating damaged lung tissue. Researcher Ya-Wen Chen, PhD, hopes her project will ultimately help to improve lung function in people with conditions such as chronic obstructive pulmonary disease…
The U.S. Food and Drug Administration (FDA) has granted Organicell Regenerative Medicine permission to begin a clinical trial testing the company’s lead product, Zofin, in people with chronic obstructive pulmonary disease (COPD). The approved trial design will be a double-blinded, placebo-controlled, phase 1/2 trial to assess the…
In a pilot Phase 2 study, inhaled hyaluronan — which uses sugar secreted by living tissue that acts as a scaffold for cells — treated people with acute exacerbations of chronic obstructive pulmonary disease (COPD). The therapy was found to improve lung function, ease respiratory failure, and…
Get regular updates to your inbox.